All Eyes On $KOAN As Mega-Merger Takes Shape

Checkers
Sep 30
3 min read

If you've been around the OTC for a while, you know that fall means two things: football and mergers. But while everyone knows it's a Chiefs–Eagles rematch coming this year, not everyone knows the biggest merger of 2025 could be happening right now with

Apollo Biowellness, Inc. (OTCID: $KOAN). KOAN announced it plans to merge with Revive Regenerative, and the result will be a company operating at the center of two of the fastest-growing sectors in modern medicine: energy-based aesthetics and regenerative biologics.

On day one KOAN will kick off with a full suite of fresh products Revive, an established pipeline from KOAN's Evo Bio, and a seasoned leadership team ready to take it the distance. The approach is quite simple: sell clinics the expensive devices that get patients in the door, then keep selling them the high-margin biologic treatments that those patients keep coming back for.

Three bottles labeled "PERIO," "ELIXIR," and "GRO" on a white background. Text above highlights clinical grade, CGMP lab, and patented tech.

Post-merger KOAN will run the operation through two divisions. First, there's Revive Lasers, the comprehensive device division built to equip the modern aesthetic practice. The portfolio includes the workhorse systems that drive clinic revenue like the iBlaze CO2 for skin resurfacing, Fraclight IPL for pigmentation, and Retraction RF for non-invasive skin tightening.

The second leg of the structure is Revive Biologics, which is designed to set a the standard by delivering true clinical-grade regenerative therapies. This standard of quality is backed by strict protocols: every biologic is manufactured in cGMP-compliant, FDA-registered labs, sold only to licensed medical practitioners, and is so biologically active it requires overnight shipping in frozen packaging to maintain viability. Flagship products like EVO ELIXIR for skin and EVO GRO for hair are sophisticated exosome therapies packed with hundreds of growth factors designed to regenerate tissue at a cellular level. This creates a recurring revenue stream of high-margin, proprietary consumables that clinics need to keep ordering because patients are seeing real results.

Bar graph of the exosomes market growth from 2020-2030 by product/service. Purple, dark blue, and light blue bars rise, showing a 28.7% CAGR.

Revive Regenerative, and thus KOAN, is positioned at the convergence of two massive markets. The global aesthetic devices market is projected to grow to almost $38 billion by 2029, while the regenerative biologics and exosome market is experiencing hyper-growth with forecasts projecting growth of over 28% a year. Revive is one of the only pure-play companies built to capture both tailwinds simultaneously, offering the integrated device-plus-biologic protocols that are rapidly becoming the new standard of care.

Execution of the vision is driven by a team of industry veterans with proven track records. The roster includes incoming CEO James Palastra who was a senior executive at Cynosure, which grew to ~$400 million in revenue before it was acquired for over $1.6 billion. He's joined by Chief Commercial Officer Christopher Chambers and VP Robert Daley, both leaders with histories of delivering high-margin revenue growth. This is the same leadership profile that has previously built and exited major players in the space, and many of these faces have played this game a few times before.

Three black-and-white portraits of business executives with titles: CEO, VP, and CCO. Neutral background, formal attire, no visible emotions.

KOAN currently has a market cap just over $3 million, and what makes this so interesting is post-merger the company will already be operating with an established pipeline AND is bound by the merger agreement to achieve $25 million in revenue with $2.5 million in positive earnings in 2026. For context, established NASDAQ-listed peers like $INMD and $ORGO have market capitalizations of around $950 million and $540 million respectively.

We all know the OTC is a game of cycles, and fall always seems to be that time of year where you can find some incredible opportunities. This KOAN merger fuses stability with an industry undergoing explosive growth, and brings with it a leadership team with a billion-dollar playbook. If the company gets anywhere close to its 2026 goals, KOAN could shape up as one of the best mergers to hit the OTC in 2025.

Disclaimer: The content provided is for informational purposes only and does not constitute a comprehensive analysis of the mentioned topics. All views, opinions, and predictions are those of the author at the time of writing and may change. This should not be considered as investment advice or a solicitation to buy or sell any securities. Readers are strongly advised to review the company’s official disclosures, filings, and updates to ensure accurate and current information. Always conduct your own research or consult with a financial advisor before making investment decisions. The author and publisher are not liable for any losses or damages arising from the use of this information. Please remember that all investments carry risks, including potential loss of principal.